Hemostemix (TSE:HEM) has released an update.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Hemostemix Inc., a pioneering autologous stem cell therapy company, has announced a private placement aiming to raise up to $4,000,000 through the sale of Common Shares and Warrants. This strategic financing move is expected to fuel the company’s growth and advance the development and commercialization of its innovative blood-based stem cell therapeutic platform and lead product, ACP-01.
For further insights into TSE:HEM stock, check out TipRanks’ Stock Analysis page.